IPP Bureau
Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
By IPP Bureau - November 09, 2025
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
By IPP Bureau - November 09, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
By IPP Bureau - November 09, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
By IPP Bureau - November 09, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
By IPP Bureau - November 09, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
By IPP Bureau - November 09, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr
By IPP Bureau - November 08, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
By IPP Bureau - November 08, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Alembic receives FDA final approval for Sumatriptan Injection USP
By IPP Bureau - November 08, 2025
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Alembic announces USFDA final approval for Dasatinib Tablets
By IPP Bureau - November 08, 2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Lupin Bioresearch Center receives zero observations from USFDA
By IPP Bureau - November 08, 2025
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
By IPP Bureau - November 07, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
By IPP Bureau - November 07, 2025
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
By IPP Bureau - November 07, 2025
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
